279 related articles for article (PubMed ID: 25344136)
1. [Cost-utility analysis of triple therapy with telaprevir in treatment-naïve hepatitis C patients].
Buti M; Gros B; Oyagüez I; Andrade RJ; Serra MA; Turnes J; Casado MA
Farm Hosp; 2014 Sep; 38(5):418-29. PubMed ID: 25344136
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in previously untreated chronic hepatitis C genotype 1 patients.
Cure S; Bianic F; Gavart S; Curtis S; Lee S; Dusheiko G
J Med Econ; 2014 Jan; 17(1):65-76. PubMed ID: 24160335
[TBL] [Abstract][Full Text] [Related]
3. Cost utility of telaprevir-PR (peginterferon-ribavirin) versus boceprevir-PR and versus PR alone in chronic hepatitis C in The Netherlands.
Vellopoulou A; van Agthoven M; van der Kolk A; de Knegt RJ; Berdeaux G; Cure S; Bianic F; Lamotte M
Appl Health Econ Health Policy; 2014 Dec; 12(6):647-59. PubMed ID: 25103219
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in treatment-experienced chronic hepatitis C genotype 1 patients.
Cure S; Bianic F; Gavart S; Curtis S; Lee S; Dusheiko G
J Med Econ; 2014 Jan; 17(1):77-87. PubMed ID: 24032626
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of triple therapy with protease inhibitors in treatment-naive hepatitis C patients.
Blázquez-Pérez A; San Miguel R; Mar J
Pharmacoeconomics; 2013 Oct; 31(10):919-31. PubMed ID: 24000086
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of boceprevir for the treatment of chronic hepatitis C virus genotype 1 infection in Portugal.
Elbasha EH; Chhatwal J; Ferrante SA; El Khoury AC; Laires PA
Appl Health Econ Health Policy; 2013 Feb; 11(1):65-78. PubMed ID: 23355388
[TBL] [Abstract][Full Text] [Related]
7. A cost utility analysis of simeprevir used with peginterferon + ribavirin in the management of genotype 1 hepatitis C virus infection, from the perspective of the UK National Health Service.
Westerhout K; Treur M; Mehnert A; Pascoe K; Ladha I; Belsey J
J Med Econ; 2015; 18(10):838-49. PubMed ID: 25903830
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of Telaprevir combination therapy for chronic hepatitis C.
Brogan AJ; Talbird SE; Thompson JR; Miller JD; Rubin J; Deniz B
PLoS One; 2014; 9(3):e90295. PubMed ID: 24603445
[TBL] [Abstract][Full Text] [Related]
9. [Cost-effectiveness analysis of sofosbuvir, peginterferon and ribavirin in patients with chronic hepatitis C: Early treatment in the initial stage of fibrosis vs. delayed treatment in advanced fibrosis].
Buti M; Domínguez-Hernández R; Oyagüez I; Casado MÁ
Gastroenterol Hepatol; 2016; 39(7):449-57. PubMed ID: 27084669
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of peginterferon alfa-2a (40kDa) plus ribavirin in patients with HIV and hepatitis C virus co-infection.
Hornberger J; Torriani FJ; Dieterich DT; Bräu N; Sulkowski MS; Torres MR; Green J; Patel K
J Clin Virol; 2006 Aug; 36(4):283-91. PubMed ID: 16765638
[TBL] [Abstract][Full Text] [Related]
11. Cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C.
Sullivan SD; Craxi A; Alberti A; Giuliani G; De Carli C; Wintfeld N; Patel KK; Green J
Pharmacoeconomics; 2004; 22(4):257-65. PubMed ID: 14974875
[TBL] [Abstract][Full Text] [Related]
12. Pharmacoeconomic analysis of the treatment of chronic hepatitis C with peginterferon alfa-2a or peginterferon alfa-2b plus ribavirin in Spain.
Turnes J; Romero-Gómez M; Planas R; Solà R; García-Samaniego J; Diago M; Crespo J; Calleja JL; Rubio-Terrés C; Ventayol P
Gastroenterol Hepatol; 2013 Nov; 36(9):555-64. PubMed ID: 24119723
[TBL] [Abstract][Full Text] [Related]
13. Cost-Effectiveness of Genotype 1 Chronic Hepatitis C Virus Treatments in Patients Coinfected with Human Immunodeficiency Virus in the United States.
Saab S; Virabhak S; Parisé H; Johnson S; Wang A; Misurski D; Gonzalez YS; Juday T
Adv Ther; 2016 Aug; 33(8):1316-30. PubMed ID: 27342742
[TBL] [Abstract][Full Text] [Related]
14. Personalized cost-effectiveness of boceprevir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C.
Petta S; Cabibbo G; Enea M; Macaluso FS; Plaia A; Bruno R; Gasbarrini A; Bruno S; Craxì A; Cammà C;
Dig Liver Dis; 2014 Oct; 46(10):936-42. PubMed ID: 25066806
[TBL] [Abstract][Full Text] [Related]
15. Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration.
Chan K; Lai MN; Groessl EJ; Hanchate AD; Wong JB; Clark JA; Asch SM; Gifford AL; Ho SB
Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1503-10. PubMed ID: 23707354
[TBL] [Abstract][Full Text] [Related]
16. Boceprevir for Chronic Genotype 1 Hepatitis C Virus in the Current Health Care Setting in Greece: A Cost-effectiveness Analysis.
Athanasakis K; Ferrante SA; Kyriopoulos II; Petrakis I; Hill M; Retsa MP; Kyriopoulos J
Clin Ther; 2015 Jul; 37(7):1529-40. PubMed ID: 26031617
[TBL] [Abstract][Full Text] [Related]
17. Peginterferon alfa-2a versus peginterferon alfa-2b as initial treatment of hepatitis C virus infection: a cost-utility analysis from the perspective of the Veterans Affairs Health Care System.
Yeh WS; Armstrong EP; Skrepnek GH; Malone DC
Pharmacotherapy; 2007 Jun; 27(6):813-24. PubMed ID: 17542764
[TBL] [Abstract][Full Text] [Related]
18. A multidisciplinary support programme increases the efficiency of pegylated interferon alfa-2a and ribavirin in hepatitis C.
Carrión JA; Gonzalez-Colominas E; García-Retortillo M; Cañete N; Cirera I; Coll S; Giménez MD; Márquez C; Martin-Escudero V; Castellví P; Navinés R; Castaño JR; Galeras JA; Salas E; Bory F; Martín-Santos R; Solà R
J Hepatol; 2013 Nov; 59(5):926-33. PubMed ID: 23811030
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of telaprevir in patients with genotype 1 hepatitis C in Australia.
Warren E; Wright A; Jones B
Value Health; 2014 Dec; 17(8):792-800. PubMed ID: 25498774
[TBL] [Abstract][Full Text] [Related]
20. The economics of treating chronic hepatitis C patients with peginterferon alpha-2a (40 kDa) plus ribavirin presenting with persistently normal aminotransferase.
Hornberger J; Farci P; Prati D; Zeuzem S; Green J; Patel KK
J Viral Hepat; 2006 Jun; 13(6):377-86. PubMed ID: 16842440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
